Bhagat Chandani, Gurnani Nishant, Godara Suraj, Mathur Rajan, Goel Ankur, Meshram Hari Shankar
Nephrology, Institute of Liver and Biliary Sciences, New Delhi, IND.
Urology, Employees' State Insurance Corporation (ESIC) Hospital, Faridabad, IND.
Cureus. 2024 Jan 5;16(1):e51693. doi: 10.7759/cureus.51693. eCollection 2024 Jan.
Introduction Kidney transplant recipients (KTRs) are prone to coronavirus disease 2019 (COVID-19) disease secondary to chronic immunosuppressive therapy. There have been differences in mortality and morbidity amongst the general population with different COVID-19 waves. This study is done to understand the effects of different COVID-19 waves amongst KTRs. Methods This was a retrospective single-centre trial from a high-volume transplant centre in North India. The immunosuppression protocol was changed according to national guidelines, and predictors of survival were evaluated. Results A total of 62 patients got infected during the first COVID-19 wave (March 2020 to February 2021) and 50 patients during the second COVID-19 wave (March 2021 to December 2021). Analysis showed a higher incidence of severe COVID-19 disease (79% vs. 50%) in the first wave, while the rest of the baseline parameters were similar in both waves. Mortality was similar in both groups. In both groups, severe COVID-19 disease, the requirement of hospitalisation, invasive oxygen therapy, and CT score findings were significant predictors of survival. There was no change in survival with respect to immunosuppression modification. Allograft dysfunction was more common in the second wave (7 vs. 1). Baseline creatinine was significantly associated with allograft dysfunction in follow-up. Conclusion Patients had severe COVID-19 disease during the first wave; however, poor availability of healthcare services during the second wave led to more patients with allograft dysfunction. Though immunosuppression change is necessary to prevent flare-ups of COVID-19 infection, it is not associated with survival benefits.
引言
肾移植受者(KTRs)由于长期接受免疫抑制治疗,易感染2019冠状病毒病(COVID-19)。在不同的COVID-19疫情波次中,普通人群的死亡率和发病率存在差异。本研究旨在了解不同COVID-19疫情波次对KTRs的影响。
方法
这是一项来自印度北部一家大型移植中心的回顾性单中心试验。免疫抑制方案根据国家指南进行了调整,并对生存预测因素进行了评估。
结果
在第一波COVID-19疫情(2020年3月至2021年2月)期间,共有62例患者感染,在第二波COVID-19疫情(2021年3月至2021年12月)期间,有50例患者感染。分析显示,第一波中重症COVID-19疾病的发病率较高(79%对50%),而两波的其他基线参数相似。两组的死亡率相似。在两组中,重症COVID-19疾病、住院需求、有创氧疗和CT评分结果都是生存的重要预测因素。免疫抑制调整对生存没有影响。移植肾功能不全在第二波中更为常见(7例对1例)。随访中,基线肌酐水平与移植肾功能不全显著相关。
结论
患者在第一波疫情期间患有重症COVID-19疾病;然而,第二波疫情期间医疗服务可及性差导致更多患者出现移植肾功能不全。虽然改变免疫抑制对于预防COVID-19感染的复发是必要的,但它与生存获益无关。